Compare CNMD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNMD | URGN |
|---|---|---|
| Founded | 1970 | 2004 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2016 |
| Metric | CNMD | URGN |
|---|---|---|
| Price | $39.96 | $24.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $48.00 | $29.29 |
| AVG Volume (30 Days) | 356.4K | ★ 649.8K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | $1,128,000.00 |
| Revenue This Year | $0.82 | $127.17 |
| Revenue Next Year | $5.48 | $73.82 |
| P/E Ratio | $25.89 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $33.21 | $3.42 |
| 52 Week High | $60.80 | $30.00 |
| Indicator | CNMD | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 72.75 |
| Support Level | $39.36 | $18.55 |
| Resistance Level | $46.08 | $30.00 |
| Average True Range (ATR) | 1.46 | 1.28 |
| MACD | 0.65 | 0.61 |
| Stochastic Oscillator | 93.47 | 99.73 |
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.